Response to 2'-deoxycoformycin after failure of interferon-α in nonsplenectomized patients with hairy cell leukemia

Two patients with hairy cell leukemia with massive splenomegaly and severe pancytopenia were treated with recombinant alpha-A interferon (IFN-alpha-2a). There was no significant response to a trial of IFN-alpha-2a (11 and 20 weeks) with respect to blood counts or spleen size. Subsequent treatment wi...

Full description

Saved in:
Bibliographic Details
Published in:Blood 1986-07, Vol.68 (1), p.297-300
Main Authors: FOON, K. A, NAKANO, G. M, KOLLER, C. A, LONGO, D. L, STEIS, R. G
Format: Article
Language:English
Subjects:
Adult
Aged
Biological and medical sciences
Coformycin - analogs & derivatives
Coformycin - therapeutic use
Female
Humans
Interferon Type I - therapeutic use
Leukemia, Hairy Cell - blood
Leukemia, Hairy Cell - drug therapy
Leukemia, Hairy Cell - therapy
Male
Medical sciences
Neuropharmacology
Pentostatin
Pharmacology. Drug treatments
Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease)
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Ribonucleosides - therapeutic use
Splenomegaly
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Two patients with hairy cell leukemia with massive splenomegaly and severe pancytopenia were treated with recombinant alpha-A interferon (IFN-alpha-2a). There was no significant response to a trial of IFN-alpha-2a (11 and 20 weeks) with respect to blood counts or spleen size. Subsequent treatment with 2'-deoxycoformycin (dCF) for 8 consecutive weeks (4 mg/m2/wk) resulted in normalization of spleen size and a normalization of peripheral blood counts and bone marrow in one patient. The second patient demonstrated a reduction in spleen size and improved blood counts following 9 weeks of dCF therapy but eventually became refractory. This demonstrates that dCF is non-cross-resistant with interferon and confirms the efficacy of dCF in nonsplenectomized patients.
ISSN:0006-4971
1528-0020
DOI:10.1182/blood.V68.1.297.297